<DOC>
	<DOCNO>NCT03013517</DOCNO>
	<brief_summary>This open-label , follow-up study subject complete PEPITES study . Subjects offer enrollment follow-up study receive Viaskin Peanut 250 Î¼g 2 additional year previously active treatment PEPITES study , 3 year previously placebo PEPITES study .</brief_summary>
	<brief_title>Follow-up PEPITES Study Evaluate Long-term Efficacy Safety Viaskin Peanut Children</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Subjects complete PEPITES study . Generalized dermatologic disease ( example , active atopic dermatitis , uncontrolled generalize active eczema , ichthyosis vulgaris ) extend widely skin especially back arm intact zone apply Viaskin patch . Diagnosis asthma evolve severe , unstable uncontrolled asthma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Allergy</keyword>
	<keyword>food allergy</keyword>
	<keyword>viaskin</keyword>
	<keyword>peanut</keyword>
	<keyword>epicutaneous</keyword>
</DOC>